Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
FE-203799 (apraglutide) is a once-weekly , a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog. It is being evaluated for the treatment of short bowel syndrome.
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2025
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
Details : FE-203799 (apraglutide) is a once-weekly , a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog. It is being evaluated for the treatment of short bowel syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 14, 2025
Details:
FE-203799 (apraglutide) is a once-weekly , a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog. It is being evaluated for the treatment of short bowel syndrome.
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 29, 2025
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Apraglutide NDA Begins, Ironwood Reveals New Corporate Updates
Details : FE-203799 (apraglutide) is a once-weekly , a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog. It is being evaluated for the treatment of short bowel syndrome.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 29, 2025
Details:
FE-203799 (apraglutide) is a long-acting GLP-2 analog under evaluation for steroid-refractory gastrointestinal acute graft-versus-host disease.
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ironwood Reports Positive Phase II Results for Apraglutide in aGVHD
Details : FE-203799 (apraglutide) is a long-acting GLP-2 analog under evaluation for steroid-refractory gastrointestinal acute graft-versus-host disease.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 28, 2024
Details:
FE-203799 (apraglutide) is an investigational, next-generation, long-acting synthetic GLP-2 analog. It is being evaluated for the treatment of short bowel syndrome with intestinal failure.
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 29, 2024
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ironwood Announces Positive Topline Phase 3 Results for Apraglutide in SBS
Details : FE-203799 (apraglutide) is an investigational, next-generation, long-acting synthetic GLP-2 analog. It is being evaluated for the treatment of short bowel syndrome with intestinal failure.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
February 29, 2024
Details:
Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Ironwood Pharmaceuticals
Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition December 12, 2023
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Ironwood Pharmaceuticals
Deal Size : $1,000.0 million
Deal Type : Acquisition
Ironwood Announces the Completion of Squeeze-Out Merger with VectivBio
Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $1,000.0 million
December 12, 2023
Details:
Apraglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2023
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation
Details : Apraglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 21, 2023
Details:
Apraglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Apraglutide,Paracetamol
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2023
Lead Product(s) : Apraglutide,Paracetamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Apraglutide on Gastric Emptying
Details : Apraglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 16, 2023
Details:
Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Ironwood Pharmaceuticals
Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition May 22, 2023
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Ironwood Pharmaceuticals
Deal Size : $1,000.0 million
Deal Type : Acquisition
Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $1,000.0 million
May 22, 2023
Details:
Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Asahi Kasei Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 13, 2023
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Asahi Kasei Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
Details : Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 13, 2023
Details:
Apraglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Lead Product(s): Apraglutide,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 31, 2023
Lead Product(s) : Apraglutide,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apraglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
